Market Size of France Drug Delivery Devices Industry
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| Historical Data Period | 2019 - 2022 |
| CAGR | 5.20 % |
| Market Concentration | Medium |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
France Drug Delivery Devices Market Analysis
The French drug delivery devices market is anticipated to expand at a CAGR of 5.2% over the forecast period.
With the emergence of the COVID-19 pandemic, most pharmaceutical companies and governments have been/are working to provide adequate medical therapy to COVID-19 patients, and drug delivery devices are likely to play an essential role in this context. For example, large-scale vaccination programs are being implemented worldwide to immunize people against the SARS-COV-2 virus. However, many companies are still working on more efficient ways of delivering COVID-19 therapeutics to patients and are investing heavily in it, which is expected to impact the drug delivery market significantly. For instance, in January 2022, the BioMAP research team from the Infectiology and Public Health (ISP) joint research unit run by INRAE and the Université de Tours developed a protein vaccine candidate for nasal administration to project against COVID-19 blocking all transmission of the virus. The Ministry of Higher Education, Research, and innovation supports the project and is accompanied by the National Agency for AIDS Research (ANRS). As a result, COVID-19 was predicted to impact the drug delivery market's growth substantially. Additionally, the market is anticipated to resume its rise during the projection period as more research and development is undertaken on COVID-19 vaccines and all restrictions are removed.
The rising prevalence of chronic diseases, technological advancements, and growth in the biologics market are some key factors driving the development of the France drug delivery devices market. Many disorders, including cardiovascular disease and diabetes, can benefit from targeted drug administration. The most important application of targeted medication delivery is the treatment of malignant tumors. As a result, the increasing prevalence of these disorders is likely to drive market expansion throughout the forecast period. For instance, the high burden of cancer can be explained by the latest statistics provided by the International Agency for Research on Cancer published GLOBOCAN 2020 report, which stated that in 2020, there were an estimated 467,965 new cancer cases diagnosed, where the male population accounted for 260,169 cases followed by female population with 207,796 cases. This shows a high burden of cancer among the target population. As a result, the population's increasing reliance on various drug types, including chemotherapy and intravenous therapy, is projected to fuel the market's expansion.
Thus, all the mentioned factors are expected to boost market growth over the forecast period. However, the risk of needlestick injury may restrain market growth over the forecast period.
France Drug Delivery Devices Industry Segmentation
As per the scope of the report, drug delivery devices or systems are the tools that are used to deliver the drug through the specific route of administration. It enables the introduction of therapeutic substances in the body. The market is segmented by route of administration (injectable, topical, and other routes of administration), application (cancer, cardiovascular, diabetes, infectious diseases, and other applications), and end user (hospitals, ambulatory surgical centers, and other end users). The report offers the value (in USD million) for the above segments.
| By Route of Administration | |
| Injectable | |
| Topical | |
| Other Routes of Administration |
| By Application | |
| Cancer | |
| Cardiovascular | |
| Diabetes | |
| Infectious diseases | |
| Other Applications |
| By End User | |
| Hospitals | |
| Ambulatory Centers | |
| Other End Users |
France Drug Delivery Devices Market Size Summary
The French drug delivery devices market is poised for significant growth, driven by several key factors. The ongoing impact of the COVID-19 pandemic has underscored the critical role of drug delivery devices in facilitating large-scale vaccination and therapeutic efforts. This has led to increased investment and innovation in the sector, with companies exploring more efficient delivery methods for COVID-19 therapeutics. As research and development continue, the market is expected to regain momentum, supported by advancements in vaccine technology and the easing of pandemic-related restrictions. Additionally, the rising prevalence of chronic diseases such as cancer, cardiovascular conditions, and diabetes is fueling demand for targeted drug delivery solutions. The growing biologics market and technological advancements further contribute to the market's expansion, as they enable more effective treatment options for these conditions.
Strategic initiatives by key market players also play a crucial role in shaping the French drug delivery devices market. Companies are actively engaging in product launches, mergers, acquisitions, and partnerships to enhance their market presence and drive innovation. Notable collaborations, such as those between Sanofi and Roche, aim to advance connected insulin pen technologies, while BioCorp's smart insulin pen device exemplifies the integration of digital solutions in diabetes care. The increasing burden of infectious diseases, including HIV, is another factor propelling market growth, as it heightens the demand for effective drug delivery systems. Overall, the market is characterized by moderate competition, with major players like Pfizer, Novartis, and Roche leading the charge. These dynamics, coupled with ongoing strategic developments, are expected to sustain the market's growth trajectory over the forecast period.
France Drug Delivery Devices Market Size - Table of Contents
-
1. MARKET DYNAMICS
-
1.1 Market Overview
-
1.2 Market Drivers
-
1.2.1 Increased Prevalence of Chronic Diseases
-
1.2.2 Technological Advances
-
-
1.3 Market Restraints
-
1.3.1 Risk of Needlestick Injuries
-
-
1.4 Porter's Five Force Analysis
-
1.4.1 Threat of New Entrants
-
1.4.2 Bargaining Power of Buyers/Consumers
-
1.4.3 Bargaining Power of Suppliers
-
1.4.4 Threat of Substitute Products
-
1.4.5 Intensity of Competitive Rivalry
-
-
-
2. MARKET SEGMENTATION (Market Size By Value - USD million)
-
2.1 By Route of Administration
-
2.1.1 Injectable
-
2.1.2 Topical
-
2.1.3 Other Routes of Administration
-
-
2.2 By Application
-
2.2.1 Cancer
-
2.2.2 Cardiovascular
-
2.2.3 Diabetes
-
2.2.4 Infectious diseases
-
2.2.5 Other Applications
-
-
2.3 By End User
-
2.3.1 Hospitals
-
2.3.2 Ambulatory Centers
-
2.3.3 Other End Users
-
-
France Drug Delivery Devices Market Size FAQs
What is the current France Drug Delivery Devices Market size?
The France Drug Delivery Devices Market is projected to register a CAGR of 5.20% during the forecast period (2024-2029)
Who are the key players in France Drug Delivery Devices Market?
Becton, Dickinson and Company, Baxter International Inc., Teva Pharmaceutical Industries Ltd, Novartis Inc. and 3 M company are the major companies operating in the France Drug Delivery Devices Market.
